Pipeline

Pipeline

Guard Therapeutics' pipeline consists of the clinical drug candidate RMC-035 and preclinical drug candidates within the GTX platform.

RMC-035 is being evaluated as a kidney-protective therapy in two separate programs: open-heart surgery and kidney transplantation, respectively. Sepsis is another potential target indication for RMC-035, based on the significant unmet medical need and solid therapeutic effects observed in preclinical studies of RMC-035.

The GTX platform consists of A1M-like peptides ("GTX peptides"), which have been evaluated in numerous preclinical studies supporting their use primarily for various kidney-related diseases. A key difference that sets these peptides apart from RMC-035 is that they can be used for chronic treatment and self-administered by the patient through subcutaneous injection.